Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 1.00 |
| ▸ | APP | P05067 | 9/20 | 1.00 |
| ▸ | BCHE | P06276 | 8/20 | 1.00 |
| ▸ | RAD52 | P43351 | 1/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | PKM | P14618 | 1/20 | 0.78 |
| ▸ | UBE2N | P61088 | 1/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.78 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.78 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.78 |
| ▸ | CASP6 | P55212 | 1/20 | 0.78 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.63 |
| ▸ | TCF7L2 | Q9NQB0 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16280667 | 0.92 | CASP6 (0.92) | ACHEAPPBCHERAD52KDM4E | |
| SCHEMBL12175837 | 0.89 | RAD52 (1.00) | ACHEAPPBCHERAD52KDM4E | |
| SCHEMBL3639768 | 0.84 | RAD52 (0.82) | ACHEAPPBCHERAD52KDM4E | |
| SCHEMBL16280669 | 0.84 | ACHE (1.00) | ACHEAPPBCHERAD52KDM4E | |
| SCHEMBL8892633 | 0.83 | RAD52 (0.76) | ACHEAPPBCHERAD52KDM4E | |
| SCHEMBL16280679 | 0.82 | ACHE (0.80) | ACHEAPPBCHERAD52KDM4E | |
| SCHEMBL23748460 | 0.81 | RAD52 (0.77) | ACHEAPPBCHERAD52KDM4E | |
| SCHEMBL2583542 | 0.81 | RAD52 (0.82) | ACHEAPPBCHERAD52KDM4E | |
| SCHEMBL2590671 | 0.81 | RAD52 (0.82) | ACHEAPPBCHERAD52KDM4E | |
| SCHEMBL2590855 | 0.81 | RAD52 (0.82) | ACHEAPPBCHERAD52KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2010-12-16 | — | — | US | claimed |
| EP-2173346-A2 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | Summit Corporation Plc (GB) | 2010-04-14 | — | — | EP | claimed |
| WO-2009001060-A2 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | SUMMIT CORPORATION PLC (GB) | 2008-12-31 | — | — | WO | claimed |
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2010-12-16 | — | — | US | disclosed |
| EP-2173346-A2 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | Summit Corporation Plc (GB) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009001060-A2 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | SUMMIT CORPORATION PLC (GB) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | TPX2, DCXR, RRM2 | ACHE 2789/4885APP 3840/4885BCHE 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.